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Abstract
Main purpose Voreloxin is a Wrst-in-class anticancer
quinolone derivative that intercalates DNA and inhibits
topoisomerase II, inducing site-selective DNA damage.
Voreloxin is in clinical studies, as a single agent and in
combination with cytarabine, for the treatment of acute
myeloid leukemia (AML). The preclinical studies reported
here were performed to investigate the activity of voreloxin
alone and in combination with cytarabine, in support of the
clinical program.
Research questions Is single agent voreloxin active in
preclinical models of AML? Does the combination of vore-
loxin and cytarabine enhance the activity of either agent
alone?
Methods Inhibition of proliferation was studied in three
cancer cell lines: HL-60 (acute promyelocytic leukemia),
MV4-11 (AML), and CCRF-CEM (Acute lymphoblastic
leukemia). Combination index (CI) analysis established the
eVect of the drugs in combination. A mouse model of bone
marrow ablation was used to investigate in vivo eYcacy of
the drugs alone and in combination. Peripheral white blood
cell and platelet counts were followed to assess marrow
impact and recovery.
Results Voreloxin and cytarabine alone and in combina-
tion exhibited cytotoxic activity in human leukemia cell
lines and in vivo. The two drugs had additive or synergistic
activity in vitro and supra-additive activity in vivo. Bone
marrow ablation was accompanied by reductions in periph-
eral white blood cells and platelets that were reversible
within 1 week, consistent with the AML treatment para-
digm.
Conclusions These data support ongoing clinical evalua-
tion of voreloxin both alone and in combination with cyt-
arabine for the treatment of AML.
Keywords AML · Cytarabine · Voreloxin · Anthracycline · 
Topoisomerase II · Bone marrow ablation
Introduction
The standard treatment for newly diagnosed acute myeloid
leukemia (AML) has not changed appreciably in the last
few decades. Anthracyclines, along with the anthracenedi-
one mitoxantrone, in combination with cytarabine, a nucle-
oside analog, remain the mainstays of treatment [28, 29].
Despite the eYcacy of anthracycline-based therapies,
patients with AML typically relapse and many fail to
respond to their initial induction therapy [28, 29]. Therapy
for relapsed AML is rarely curative, unless the patient
undergoes an allogeneic bone marrow transplant (BMT),
and most patients die from their disease [23, 28, 29]. Given
that AML is primarily a disease of older patients, with a
median age of diagnosis of 67 years, only a minority of
patients will be eligible for BMT [30]. Clearly a need exists
for alternative therapies for the treatment of this disease,
including opportunities for bridging to the potentially cura-
tive option of hematopoietic stem cell transplant.
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Voreloxin is a Wrst-in-class anticancer quinolone deriva-
tive that is currently in clinical studies as a single agent for
the newly diagnosed elderly population, and in combination
with cytarabine for relapsed/refractory AML. Voreloxin’s
mechanism of action is similar to that of the anthracyclines
[4] in that it is a DNA damaging agent that intercalates
DNA and poisons topoisomerase II [12]. However, because
voreloxin is derived from a distinct chemical scaVold, both
mechanistic and pharmaceutical features diVerentiate this
new agent. The naphthyridine core, a member of the quino-
lone family, is less chemically reactive than that of the
anthracyclines. The voreloxin-induced DNA damage, in
contrast to anthracyclines, is site-selective, targeting GC
rich regions similar to quinolone antibacterial drugs [12].
Voreloxin also has a favorable pharmacokinetic proWle,
with low clearance (2 L/h/m2), long terminal half-life
(22 h), and dose-proportional exposure [1]. Voreloxin’s
50 L/m2 volume of distribution at steady state exceeds total
body water, but is at least eightfold lower than that of the
anthracycline daunomycin [2, 27]. Taken together, the site-
selective DNA damage and more limited distribution to
normal tissues suggest a lower potential for the oV-target
organ toxicities common to the anthracyclines [15]. Thus
far in clinical studies, the dose-limiting toxicities observed
with voreloxin are reversible and include oral mucositis
(leukemias) [18, 25] and neutropenia with an acceptable
frequency of febrile neutropenia (solid tumors) [1].
EYcacy of the anthracyclines and mitoxantrone may be
limited by sensitivity to the common tumor resistance
mechanism of P-glycoprotein (P-gp) eZux, the expression
of which is an independent prognostic factor for response to
therapy in AML [7, 21, 24]. In contrast, voreloxin is not a
P-gp substrate [8, 14], and activity has been reported in
anthracycline-resistant  preclinical models [14] and in
patients with relapsed/refractory AML or platinum-resis-
tant ovarian cancer for whom anthracycline-based therapies
have failed [13]. The P-gp resistance mechanism is of par-
ticular relevance to AML, as both older and relapsed
patients often express higher levels of this eZux pump [28].
Voreloxin is being evaluated for the treatment of AML.
In order to support this clinical investigation, voreloxin was
evaluated alone and in combination with cytarabine in vitro
in human leukemia cell lines, and in vivo in a mouse model
of bone marrow ablation and recovery.
Materials and methods
Materials
For in vitro cell viability assays, voreloxin was dissolved
in 0.17% methanesulfonic acid (Sigma Chemical Co., St.
Louis, MO), forming a stock solution of 10 mM. The
solution was stored at room temperature until it was
diluted to working concentrations in fresh growth media.
For vehicle-treated controls, an equivalent dilution of
0.17% methanesulfonic acid was added to growth media
prior to addition to the cells. A stock solution of cytara-
bine (Cytosine -D-arabinofuranoside HCl, Sigma) was
prepared in sterile water at 30 mM and stored at ¡20°C
until it was diluted for use with fresh growth media. The
clinical formulation of voreloxin (10 mg/ml) was used for
in vivo studies and further diluted for injection into mice
by dilution with vehicle (0.17% methanesulfonic acid in
5% sorbitol (Sigma)). Cytarabine (100 mg/vial, Henry
Schein, Inc., Melville, NY) was reconstituted in sterile
water at 20 mg/ml and then diluted further if necessary for
injection.
Cell viability assays
CCRF-CEM (acute lymphoblastic leukemia, ALL), MV4-
11 (biphenotypic B myelomonocytic leukemia), and HL-
60 (acute promyelocytic leukemia) cell lines, obtained
from the American Type Culture Collection (ATCC,
Manassas, VA), were grown in RPMI-1640 + 10% fetal
bovine serum (FBS) at 37°C in a humidiWed atmosphere
of 5% CO2. Cells were seeded in opaque, clear bottom 96-
well plates at 1 £ 105/well in growth media. Voreloxin
and/or cytarabine were serially diluted in growth media
and added to the appropriate wells. Initial concentrations
of voreloxin: CCRF-CEM, 1.5 M; MV4-11, 1.0 M;
HL-60, 9 M. Initial concentrations of cytarabine: CCRF-
CEM, 0.150 M; MV4-11, 15 M; HL-60, 9 M. In the
Wnal well of the dilution series, media with vehicle were
added to the cells. CellTiter-Glo Luminescent Cell Via-
bility Assay (Promega, Madison, WI) was performed as
per manufacturer’s protocol, and the median of three rep-
licate wells was used for IC50 curve generation. The IC50
values were determined in GraphPad/Prism (GraphPad
Software, Inc., San Diego, CA) using non-linear regres-
sion of a sigmoidal dose response curve with a variable
slope and no constraints. The eVect of combining vore-
loxin and cytarabine was compared to the eVect achieved
with each drug alone. To provide information on the
nature of the drug interaction, the combination index (CI)
[6] was calculated for two (CCRF-CEM, MV4-11) or
three (HL-60) independent experiments according to the
method of Zhao, et al. [31] The CI values were stratiWed
as follows: CI > 1.2 the combination was antagonistic, CI
from 1.2 to 0.85 the combination was additive, and for
CI < 0.85 the combination was synergistic [5, 26]. Vore-
loxin, combined with itself, was included as a control for
additivity.Cancer Chemother Pharmacol (2010) 66:881–888 883
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Animals
CD-1 female mice (Charles River, Wilmington, MA) were
acclimated for 3 days during which time their health was
assessed daily. PuriWed water and food (PicoLab Rodent
Diet 20, #5053; Dean’s Animal Feeds, San Carlos, CA)
were provided ad libitum, and the animals were kept on a
12 h light and dark cycle. All experiments were performed
in accordance with protocols approved by the Sunesis Phar-
maceuticals, Inc. Institutional Animal Care and Use Com-
mittee and in accordance with local, state, and federal
regulations.
In vivo studies
Animals were weighed, randomized by body weight, and
assigned to the study groups before initiation of treat-
ment. Voreloxin was administered intravenously (IV) at
10 or 20 mg/kg once on day zero and once on day four
(q4d £2). Cytarabine was administered subcutaneously
(SC) at 20 or 60 mg/kg every 8 h on day zero and day four
(tid q4d £2) [3]. Tissues and blood were sampled on days
6, 8, and 12 from at least three and not greater than ten
animals per treatment group. Blood cell counts were per-
formed at Quality Clinical Labs (SRI, Palo Alto, CA) on a
Baker 9000 (Serono Baker Diagnostics, Allentown, PA)
or ADVIA 120 (Bayer Diagnostics, Tarrytown, NY).
Femurs were placed in Streck Tissue Fixative solution
(Streck Laboratories, Omaha, NE), or in 10% formalin
solution (Richard-Allan ScientiWc, Kalamazoo, MI) for
24–48 h followed by a 70% dehydrant (ethanol, isopropa-
nol, methanol, Richard-Allan ScientiWc). Femurs were
decalciWed, paraYn embedded, and sectioned at Biopa-
thology Labs (South San Francisco, CA). The four
micron sections were stained with hematoxylin-eosin
(H&E) (Biopathology Labs). H&E stained femurs were
examined and percent cellularity of the bone marrow
was determined. Digital photographs of representative
femur sections were taken on a Leica DM2000 micro-
scope (Leica Microsystems, Wetzlar, Germany) using
Image-Pro Plus v6.1 software (Media Cybernetics, Silver
Spring, MD).
Statistical analysis
For in vivo studies, the hematologic and histological
results presented are the mean and standard error (SE)
determined from each treatment group at the speciWed
time points. SigniWcant diVerences in percent bone mar-
row cellularity between treatment groups were deter-
mined using one-way ANOVA with P · 0.05 regarded
as signiWcant.
Results
Voreloxin has potent cytotoxic activity in human acute 
leukemia cell lines when used alone or in combination 
with cytarabine
The cytotoxic activities of voreloxin and cytarabine were
evaluated in human acute leukemia cell lines MV4-11, HL-
60, and CCRF-CEM. The average IC50 for voreloxin in the
AML cell lines MV4-11 and HL-60 was 95 § 8n M  a n d
884 § 114 nM, respectively. The ALL cell line, CCRF-
CEM, was also sensitive to voreloxin with an average IC50
of 166 § 0.4 nM. Cytarabine was less potent than vore-
loxin in the AML cell line MV4-11 with an average IC50 of
1,457 § 127 nM. In HL-60 cells, the average IC50 was
689 § 245 nM, while in CCRF-CEM cells cytarabine was
very active with an average IC50 of 15 § 5n M .
The activity of voreloxin in combination with cytara-
bine was then assessed using drug concentrations extrapo-
lated from individual IC50 values. When voreloxin and
cytarabine were combined, the cytotoxic activity in MV4-
11 and HL-60 cells was synergistic as demonstrated by a
leftward shift in the voreloxin IC50 curves and calculated
CIs less than 0.85 (Fig. 1a, b). In CCRF-CEM cells, com-
bining voreloxin with cytarabine resulted in an additive
increase in cytotoxicity with CIs of 0.85 (Fig. 1b) and
0.99 (Fig. 1a, b).
Voreloxin causes reversible bone marrow ablation alone 
or in combination with cytarabine
The activity of voreloxin was investigated in vivo by exam-
ining the eVect of the drug in a mouse model of bone mar-
row ablation and recovery. CD-1 mice were administered
vehicle, voreloxin, cytarabine, or a combination of vore-
loxin and cytarabine. Two days after completion of the
treatment cycle (day 6), femurs were isolated, and bone
marrow cellularity was assessed in hematoxylin-eosin
(H&E) stained sections. The mean bone marrow cellularity
was 95% in the vehicle-treated animals indicating that the
hematopoietic cells in the bone marrow were unaVected by
the procedures, and the marrow was normal (Fig. 2a; c i).
Administration of cytarabine at the maximum tolerated
dose (MTD), 60 mg/kg tid q4d £2, caused a 26% reduction
in bone marrow cellularity relative to vehicle by day six
(Fig. 2a). In comparison, administration of voreloxin at
MTD, 20 mg/kg q4d £2, resulted in an 80% reduction in
cellularity relative to vehicle 2 days after treatment
(Fig. 2a). In cytarabine-treated or voreloxin-treated ani-
mals, the percentage of hematopoietic cells in the marrow
decreased in association with increased signs of marrow
damage [10,  19] including dilation of sinusoids with884 Cancer Chemother Pharmacol (2010) 66:881–888
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inWltration of adipocytes and erythrocytes into the marrow
stroma (Fig. 2c ii, iii).
For the combination study, CD-1 mice received cytara-
bine at 20 mg/kg tid on days zero and four, and voreloxin at
10 mg/kg on days zero and four. Cytarabine alone at
20 mg/kg (33% MTD) had little eVect on the bone marrow
by day 6 while voreloxin alone at 10 mg/kg (50% MTD)
reduced mean bone marrow cellularity relative to vehicle
by 36% (Fig. 2b, c, iv, v). In contrast, combining the two
agents substantially enhanced the reduction in bone marrow
cellularity; an 89% reduction relative to vehicle was
observed when voreloxin (50% MTD) was combined with
the cytarabine (33% MTD) (Fig. 2b, c, vi). There was a
statistical diVerence in the cellularity of the bone marrow
following the combination treatment when comparing to
vehicle-treated animals (P < 0.001) and animals treated
with cytarabine at MTD (P < 0.001). As seen with cytara-
bine and voreloxin alone, the combination treatment caused
ablation of the marrow, dilation of sinusoids, and inWltra-
tion of adipocytes.
Concomitant reduction in peripheral lymphoid and myeloid 
cells occurred with decreased bone marrow cellularity
To determine whether the treatment-induced bone marrow
ablation was reversible, repeat studies were extended to day
12 with the inclusion of peripheral blood counts along with
bone marrow cellularity. CD-1 mice were treated with
voreloxin, cytarabine, or the two drugs combined. In ani-
mals treated with voreloxin at 20 mg/kg on days zero and
four (MTD), relative to vehicle-treated animals, bone
marrow cellularity was reduced by 78% on day 6, while in
animals treated with cytarabine at 60 mg/kg tid on days
zero and four (MTD) marrow cellularity decreased 42%
(Fig. 3a). These decreases in cellularity were reversible for
both agents with bone marrow returning to 100% cellularity
by day 12 (Fig. 3a). The bone marrow in vehicle-treated
animals was unaVected by treatment (Fig. 3a). Consistent
with results of the experiment previously described in
Fig. 2, when animals received the combination of voreloxin
(10 mg/kg q4d £2) with cytarabine (20 mg/kg tid q4d £2)
bone marrow cellularity was reduced by 91% relative to
vehicle on day 6 (Fig. 4a, D6). The marrow recovered from
combination treatment with mean cellularity returning to
90% or greater 8 days after completing treatment (Fig. 4a,
D12).
The integrity of the marrow within the vehicle-treated
animals was reXected in peripheral blood counts with
circulating neutrophils and lymphocytes counts within the
normal range, 0.5–3 £ 103/l and 2–8 £ 103/l, [9],
respectively (Fig. 3b, days 6–12). A decrease in platelet
Fig. 1 Voreloxin combined with cytarabine has additive or synergis-
tic activity in acute leukemia cell lines Viability studies were per-
formed using human acute leukemia cell lines MV4-11, HL-60, and
CCRF-CEM exposed for 72 h to serially diluted voreloxin and/or
cytarabine. a Percent viability of cells treated with voreloxin alone or
in combination: (Filled circle), voreloxin alone; (Filled inverted
triangle), voreloxin combined with cytarabine. The combination index
(CI) calculated from the curves is indicated and also shown graphically
below. b Combination index (CI): CI < 0.85 indicates synergy, CI of
0.85–1.2 indicates additivity, CI > 1.2 indicates antagonism. Each data
point represents an independent experiment. (triangle), CCRF-CEM;
(Circle), MV4-11; (Square), HL-60. Voreloxin control, voreloxin
combined with itselfCancer Chemother Pharmacol (2010) 66:881–888 885
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counts in the vehicle-treated animals on day 6 and 12 was
unexpected and likely due to aggregation of platelets in the
collected specimen (Fig. 3b). In animals treated with vore-
loxin (20 mg/kg q4d £2), the loss in bone marrow cellular-
ity was reXected in a dramatic decrease in circulating
peripheral neutrophils (mean nadir 0.03 £ 103/l) and lym-
phocytes (mean nadir 0.6 £ 103/l). Circulating platelets
in these animals dipped just below normal (1,000–
2,000 £ 103/l) [9] on days 6 and 8. With the recovery of
bone marrow cellularity, by day 12 peripheral neutrophils,
lymphocytes, and platelets rebounded to circulating levels
at or above normal (Fig. 3b).
For the cytarabine (60 mg/kg tid q4d £2)-treated ani-
mals, circulating neutrophils and platelets decreased below
normal with the nadir occurring on day 8 while peripheral
lymphocytes remained within normal circulating levels
from day zero to day 12 (Fig. 3b). The neutrophils in these
animals decreased to a mean of 0.1 £ 103/l but along with
the platelets returned to within normal range by day 12
consistent with the recovery of hematopoiesis in the bone
marrow.
Concomitant with the 91% decrease in bone marrow cel-
lularity following combination treatment was a dramatic
reduction in circulating neutrophils with a mean of only
0.03 £ 103/l at the nadir on day 8 (Fig. 4b). By compari-
son, treatment of animals with vehicle, 20 mg/kg cytarabine
or 10 mg/kg voreloxin failed to reduce peripheral neutro-
phils below the normal range of 0.5–3 £ 103/l [9]
(Fig. 4b). The circulating neutrophils in combination
treated mice returned (mean 2.6 £ 103/l) to normal by day
12 reXecting the recovery of the bone marrow (Fig. 4b).
Circulating lymphocytes showed a threefold decrease at the
nadir on day 8 although these levels still fell within the
anticipated normal range of 2–8 £ 103/l (Fig. 4b). Circu-
lating platelets in the combination treated mice were below
normal through day 8 but rebounded to acceptable levels by
day 12.
Discussion
Treatment of acute myeloid leukemia with cytarabine in
combination with an anthracycline has been the standard of
care for 30 years [28, 29]. Although initial responses to this
therapy are observed, some patients are refractory and most
will ultimately relapse [28, 29]. Here, we report preclinical
studies of voreloxin, a novel agent currently being explored
in the clinic as a potential AML therapy, both as a single
agent and in combination with cytarabine. The mechanism
of action of voreloxin bears some similarities with the anth-
racyclines, which therefore identify indications where vore-
loxin may be active clinically. In addition, key elements of
Fig. 2 Voreloxin and cytarabine, alone or in combination, ablate nor-
mal bone marrow CD-1 mice received vehicle, voreloxin, cytarabine,
or voreloxin and cytarabine in combination on day 0 and 4. On day 6,
femurs were isolated, and cellularity was assessed in H&E stained
bone marrow sections. a Percent cellularity remaining in the bone mar-
row following treatment: Vehicle, 0.17% methanesulfonic acid in 5%
sorbitol IV q4d £2 and water SC tid q4d £2; Cytarabine, 60 mg/kg SC
tid q4d £2; Voreloxin, 20 mg/kg IV q4d £2. b Percent cellularity
remaining in the bone marrow following treatment: Vehicle, as in (a);
Cytarabine, 20 mg/kg SC tid q4d £2; Voreloxin, 10 mg/kg IV q4d £2;
Combo, cytarabine, 20 mg/kg SC tid q4d £2 and voreloxin, 10 mg/kg
IV q4d £2. c H&E stained femur sections, original magniWcation
£100: i. vehicle, as in (a); ii. cytarabine, 60 mg/kg SC tid q4d £2; iii.
voreloxin, 20 mg/kg IV q4d £2; iv. cytarabine, 20 mg/kg SC tid q4d
£2; v. voreloxin, 10 mg/kg IV q4d £2; vi. combo: cytarabine, 20 mg/
kg SC tid q4d £2, and voreloxin, 10 mg/kg IV q4d £2886 Cancer Chemother Pharmacol (2010) 66:881–888
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structural, mechanistic, and pharmacologic diVerentiation
suggest that voreloxin represents an evolutionary step in the
development of topoisomerase II inhibitors. Voreloxin is a
Wrst-in-class anticancer quinolone analog, that intercalates
DNA and inhibits topoisomerase II, inducing site-selective
DNA double-strand breaks [12]. The drug is cytotoxic to
tumor cells in vitro and has potent antitumor activity in
numerous human xenograft and murine syngeneic tumor
models of diverse tissue origin [14]. These models included
both solid and hematologic tumor cell lines among which
several were multidrug resistant [14]. Voreloxin has favor-
able pharmacologic properties relative to the anthracyclines
[2, 21, 24, 27], given that it is not a P-glycoprotein substrate
[8, 14], undergoes minimal cytochrome P450 and UDP glu-
curonosyltransferase (UGT)-mediated metabolism in vivo
[8], and has low potential for cytochrome P450-mediated
drug–drug interactions.
Nanomolar concentrations of voreloxin decreased viabil-
ity of acute leukemia cell lines by 50% in vitro. The AML
cell line MV4-11, which is resistant to cytarabine in vitro,
was sensitive to voreloxin treatment. MV4-11 cells harbor
the FLT3 internal tandem duplication (ITD) mutation [20],
and AML patients with this mutation have a relatively
poorer prognosis [11]. The sensitivity of MV4-11 cells to
voreloxin suggests that it may be an eVective treatment for
AML patients with the ITD mutation.
The combination index method (CI) [6] was used to
assess the activity of voreloxin combined with cytarabine in
acute leukemia cell lines. Combining voreloxin and cytara-
bine resulted in synergistic activity in the myeloid leukemia
cell lines MV4-11 and HL-60, but only additive activity
was achieved in CCRF-CEM acute lymphoid leukemia
cells, which are highly sensitive to single agent cytarabine.
The synergistic activity in two leukemia cell lines with
voreloxin combined with cytarabine supported further
exploration of this combination in animal models.
Bone marrow cellularity was measured in femurs of
voreloxin-treated mice as a surrogate measurement for the
activity of voreloxin as a treatment for acute leukemias.
Administering voreloxin to normal mice at the MTD
reduced bone marrow cellularity by as much as 80%,
whereas cytarabine at the MTD reduced bone marrow
Fig. 3 Voreloxin or cytarabine 
at MTD causes a reversible 
decrease in myeloid and 
lymphoid cells in bone marrow 
and peripheral blood CD-1 mice 
received vehicle, voreloxin, or 
cytarabine on day 0 and 4. 
a Percent cellularity remaining 
in the bone marrow on days 6 
(D6) and 12 (D12): Vehicle, 
0.17% methanesulfonic acid in 
5% sorbitol IV q4d £2 and 
water SC tid q4d £2; 
Cytarabine, 60 mg/kg SC tid q4d 
£2; Voreloxin, 20 mg/kg IV q4d 
£2. b Peripheral blood was 
isolated on days 6, 8, and 12 for 
analysis. Neutrophils, 
lymphocytes, and platelets in 
circulation (£103/l) following 
treatment: (Filled square), 
vehicle; (Filled triangle), 
cytarabine, 60 mg/kg SC tid q4d 
£2; (Filled circle), voreloxin, 
20 mg/kg IV q4d £2. Black 
arrow represents the three 
cytarbine doses, and the gray 
arrow represents the voreloxin 
doseCancer Chemother Pharmacol (2010) 66:881–888 887
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cellularity by as much as 42%. The ablation of the bone
marrow in the voreloxin-treated animals was reversible,
with cellularity returning to 100% 1 week post-treatment,
identical to the recovery time observed in cytarabine-
treated animals. When voreloxin (50% MTD) was com-
bined with cytarabine (33% MTD), there was a dramatic
91% reduction in bone marrow cellularity, which returned
to normal within 1 week. Following voreloxin treatment
alone or in combination with cytarabine, peripheral neutro-
phils, lymphocytes, and platelets decreased in the animals but
returned to normal levels 1 week later, reXecting the recovery
of hematopoiesis. The combination dose approximates the
MTD for co-administration of the agents; decreasing the
voreloxin concentration impaired the bone marrow ablation,
and an increase in either agent was associated with increased
toxicity without signiWcant gain in eYcacy.
Cytarabine derives its cytotoxic activity by inhibiting
DNA polymerase, [22,  33] DNA ligase [32] and by its
direct incorporation into DNA, leading to termination of
synthesis and generation of DNA strand breaks [16, 17].
A possible explanation for the enhanced activity of the
combination of voreloxin and cytarabine is that cells
exit S-phase and enter G2 with cytarabine-induced DNA
damage. Upon G2 entry, voreloxin induces additional DNA
damage in the form of double-strand breaks stimulating cell
death. In addition, cells that sustain voreloxin-induced
DNA double-strand breaks may suVer from an impaired
ability to repair these breaks due to the cytarabine-induced
DNA synthesis blockade. The mechanistic basis for the
enhanced activity observed when both agents are combined
is under investigation.
The ability of voreloxin to induce a reversible bone mar-
row ablation equivalent to or better than cytarabine alone
supports the clinical investigation of voreloxin in AML.
Current clinical trials in AML include a phase II study with
single agent voreloxin in newly diagnosed elderly patients
and a phase Ib/II study with voreloxin in combination with
cytarabine in relapsed or refractory patients. In both studies
to date, complete remissions with or without platelet
recovery have been reported in voreloxin-treated patients
Fig. 4 Voreloxin and cytara-
bine in combination causes 
reversible neutropenia with a 
more modest impact on platelets 
CD-1 mice received vehicle, 
voreloxin, cytarabine, or vore-
loxin and cytarabine in combina-
tion on day 0 and 4. a Percent 
cellularity remaining in the bone 
marrow on days 6 (D6) and 12 
(D12): Vehicle, 0.17% methane-
sulfonic acid in 5% sorbitol IV 
q4d £2 and water SC tid q4d 
£2; Cytarabine, 20 mg/kg SC 
tid q4d £2; Voreloxin, 10 mg/kg 
IV q4d £2; Combo, cytarabine, 
20 mg/kg SC tid q4d £2, and 
voreloxin, 10 mg/kg IV q4d £2. 
b Peripheral blood was isolated 
on days 6, 8, and 12 for analysis. 
Absolute neutrophils, absolute 
lymphocytes, and platelets 
(£103/l) in circulation follow-
ing treatment: (Filled square), 
vehicle; (Triangle), cytarabine, 
20 mg/kg SC tid q4d £2; 
(Circle), voreloxin, 10 mg/kg IV 
q4d £2; (Filled inverted 
triangle), combo: cytarabine, 
20 mg/kg SC tid q4d £2, and 
voreloxin, 10 mg/kg IV q4d £2. 
Black arrow represents the three 
cytarbine doses, and the gray 
arrow represents the voreloxin 
dose888 Cancer Chemother Pharmacol (2010) 66:881–888
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[18,  25] demonstrating the antileukemic activity of
voreloxin and its potential as a new treatment for AML.
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